Last $18.61 USD
Change Today -0.10 / -0.53%
Volume 11.8K
FLXN On Other Exchanges
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

flexion therapeutics inc (FLXN) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/12/14 - $21.23
52 Week Low
05/1/14 - $11.06
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

flexion therapeutics inc (FLXN) Related Businessweek News

No Related Businessweek News Found

flexion therapeutics inc (FLXN) Details

Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes FX006, a sustained-release intra-articular steroid, which has completed a Phase IIb dose-ranging clinical trial to treat moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, a sustained-release intra-articular p38 MAP kinase inhibitor, which has completed a Phase IIa clinical trial intended as a therapy for patients with end-stage OA pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

20 Employees
Last Reported Date: 08/8/14
Founded in 2007

flexion therapeutics inc (FLXN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $437.1K
Co-Founder and Chief Medical Officer
Total Annual Compensation: $327.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $186.5K
Chief Business Officer
Total Annual Compensation: $178.5K
Compensation as of Fiscal Year 2013.

flexion therapeutics inc (FLXN) Key Developments

Flexion Therapeutics Announces Clinical Hold of FX006 Phase 2b Clinical Trial in Osteoarthritis of the Knee

Flexion Therapeutics, Inc. announced that the United States Food and Drug Administration (FDA) informed the company that a clinical hold has been placed on patient enrollment and dosing in an ongoing Phase 2b clinical trial evaluating FX006 in patients with osteoarthritis (OA) of the knee. FX006 is a novel, non-opioid, sustained-release, intra-articular (IA) formulation of triamcinolone acetonide (TCA) targeting moderate-to-severe OA pain. Flexion has not yet received written notice of its clinical hold from the FDA, but based on the verbal communication, the FDA indicated that the clinical hold is due to a single occurrence of an infection in the injected knee joint of a patient in the Phase 2b clinical trial.

Flexion Therapeutics, Inc. - Special Call

To discuss the clinical hold of FX006 Phase 2b Clinical Trial in Osteoarthritis of the Knee

Flexion Therapeutics, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Flexion Therapeutics, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FLXN:US $18.61 USD -0.10

FLXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FLXN.
View Industry Companies

Industry Analysis


Industry Average

Valuation FLXN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLEXION THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at